PF-06669571 In Subjects With Idiopathic Parkinson's Disease

Number of Participants With Treatment Emergent Adverse Events (All Causalities)

An adverse event (AE) was any untoward medical occurrence in a clinical investigation subject administered a product or medical device; the event need not necessarily have a causal relationship with the treatment or usage.

Time frame: Day 1 to 28 calendar days after the last dose of investigational product

Number of Participants With Supine and Standing Vital Sign Abnormalities of Potential Clinical Concern (Absolute Values)

Number of participants with supine and standing vital signs data of absolute values meeting criteria of potential clinical concern. Absolute values were analyzed for supine/standing systolic blood pressure (SBP), supine/standing diastolic blood pressure (DBP), and supine/standing pulse rate. Number of participants with vital signs data meeting the following criteria was reported: (1) absolute supine SBP \<90 millimeters of mercury (mmHg); (2) absolute standing SBP \<90 mmHg; (3)absolute supine DBP\<50mmHg; (4)absolute standing DBP\<50mmHg (5) absolute supine pulse rate \<40 beats per minute (bpm); (6) absolute supine pulse rate \>120 bpm;(7) absolute standing pulse rate \<40 bpm; (8) absolute standing pulse rate \>140 bpm.

Time frame: Screening, Days -1, 1, 7 and 8, and follow-up visit

Number of Participants With Supine and Standing Vital Sign Abnormalities of Potential Clinical Concern (Increase From Baseline)

The number of participants with vital signs data of maximum increase from baseline meeting the following criteria was reported: Criterion A: maximum increase from baseline in supine systolic BP (SBP) \>=30 millimeters of mercury (mmHg); Criterion B maximum increase from baseline in standing SBP \>=30 mmHg; Criterion C: maximum increase from baseline in supine diastolic BP(DBP) \>=20 mmHg; Criterion D: maximum increase from baseline in standing diastolic BP(DBP) \>=20 mmHg

Time frame: Screening, Days -1, 1, 7 and 8, and follow-up visit

Number of Participants With Supine and Standing Vital Sign Abnormalities (Decrease From Baseline)

The number of participants with vital signs data of maximum decrease from baseline meeting the following criteria was reported: Criterion A: maximum decrease from baseline in supine systolic BP (SBP) \>=30 mmHg; Criterion B: maximum decrease from baseline in standing SBP \>=30 mmHg; Criterion C: maximum decrease from baseline in supine diastolic BP(DBP) \>=20 mmHg; Criterion D: maximum decrease from baseline in standing diastolic BP(DBP) \>=20 mmHg

Time frame: Screening, Days -1, 1, 7 and 8, and follow-up visit

Number of Participants With Electrocardiogram (ECG) That Met Categorical Criteria for Concern (Absolute Value)

The number of participants with ECG absolute values meeting the following criteria was reported: Criterion A: maximum PR interval (time from the beginning of P wave to the start of QRS complex, corresponding to the end of atrial depolarization and onset of ventricular depolarization) \>=300 msec; Criterion B: maximum QRs complex(time from Q wave to the end of S wave, corresponding to ventricle depolarization) \>=140 msec; Criterion C: maximum QTcF interval (time from the beginning of Q wave to the end of T wave corresponding to electrical systole, corrected for heart rate using Fridericia's formula) 450-\<480 msec; Criterion D: maximum QTcF interval 480-\<500 msec; Criterion E: maximum QTcF interval (Fridericia's correction) \>=500 msec

Time frame: Screening, Days 1, 7, and 8, and follow-up visit

Primary: Number of Participants With Electrocardiogram (ECG) That Met Categorical Criteria for Concern(Increase From Baseline)

Number of participants with ECG(standard 12-lead) meeting the following criteria was reported: Criterion A: maximum PR interval increase from baseline percentage change (PctChg)\>=25/50%; Criterion B: maximum QRs complex increase from baseline PctChg \>=50%; Criterion C: maximum QTcF interval increase from baseline 30\<=change\<60 msec; Criterion D: maximum QTcF interval increase from baseline change \>=60 msec.

Time frame: Screening, Days 1, 7, and 8, and follow-up visit

Number of Participants With Laboratory Abnormalities That Met Categorical Criteria for Concern (Without Regard to Baseline Abnormality)

Number of participants with a laboratory abnormality meeting specified criteria. The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, mean corpuscular volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, platelet count, white blood cell count, absolute total neutrophils, absolute eosinophils, absolute basophils, absolute monocytes, and absolute lymphocytes),liver function(total bilirubin, direct bilirubin, aspartate, aspartate aminotransferase, alanine, alanine aminotransferase, alkaline phosphatase, total protein, and albumin), renal function (blood urea nitrogen, creatinine, and uric acid), electrolytes (sodium, potassium, chloride, calcium, and venous bicarbonate), clinical chemistry(glucose) ,and urinalysis (pH, qualitative glucose, qualitative protein, qualitative blood, qualitative ketones, qualitative bilirubin, nitrites, leukocyte esterase, urine urobilinogen, urine leukocyte, esterase and microscopy).

Time frame: Screening, Days 1, 4, and 7, and follow-up visit